dc.contributor.author | Palm, Kaia et al. | |
dc.date.accessioned | 2020-06-16T16:57:54Z | |
dc.date.available | 2020-06-16T16:57:54Z | |
dc.date.issued | 2020-05-22 | |
dc.identifier.uri | https://doi.org/10.1101/2020.05.18.20105189 | en_US |
dc.identifier.uri | https://hdl.handle.net/20.500.12663/1757 | |
dc.description.abstract | Little is known about the quality of polyclonal antibody responses in COVID-19 patients, and how it correlates with disease severity or patients' prior exposure to other pathogens. The whole polyclonal antibody repertoire in a retrospective cohort of 538 individuals was mapped against SARS-CoV-2 spike (S) glycoprotein, the main target of antibody immune responses in SARS-CoV-2 infection. Bioinformatic predictions identified 15 major B cell epitopes for S of SARS-CoV-2. Several epitopes localised in RBD of S including those spanning the ACE2-binding site, the highly conserved cryptic epitope of the neutralizing antibody of SARS-CoV, and fusion/entry domains of HR1 and HR2 of S protein of SARS-CoV-2. Intriguingly, some of these epitopes have cross-reactivity to antigens of common pathogens, potentially affecting SARS-CoV-2 infection outcome. High level of anti-Spike SARS-CoV-2 seroreactivity in populations with no history of exposure to SARS-CoV-2 is of clinical relevance and could underpin better understanding of COVID-19 pathophysiology in different populations and provide a blueprint for design of effective vaccines and developing better strategies for antibody testing. | en_US |
dc.language | English | en_US |
dc.subject | COVID-19 | en_US |
dc.subject | Coronavirus | en_US |
dc.subject | Betacoronavirus | en_US |
dc.subject | Cohort Studies | en_US |
dc.subject | Antibodies | en_US |
dc.subject | Vaccines | en_US |
dc.subject | Coronavirus Infections | en_US |
dc.title | High seroreactivity against SARS-CoV-2 Spike epitopes in a pre SARS-CoV-2 cohort: implications for antibody testing and vaccine design | en_US |
eihealth.country | Global (WHO/OMS) | en_US |
eihealth.category | Virus: natural history, transmission and diagnostics | en_US |
eihealth.type | Published Article | en_US |
eihealth.maincategory | Slow Spread / Reducir la Dispersión | en_US |
dc.relation.ispartofjournal | medRxiv | en_US |